Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1744-8603
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis ; volume:16 ; number:1 ; day:14 ; month:10 ; year:2020 ; pages:1-12 ; date:12.2020
Globalization and health ; 16, Heft 1 (14.10.2020), 1-12, 12.2020
- Urheber
-
Son, Kyung-Bok
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12992-020-00633-9
- URN
-
urn:nbn:de:101:1-2020112913563861570224
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Son, Kyung-Bok
- SpringerLink (Online service)
Ähnliche Objekte (12)
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Impact of delisting OTC medicines from reimbursement list
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
Network medicines™
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
In development new medicines for women
Regulatory roadmap for nanotechnology based medicines
Translational medicines “Ecosystem”
The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Impact of delisting OTC medicines from reimbursement list
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
Network medicines™
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
In development new medicines for women
Regulatory roadmap for nanotechnology based medicines
Translational medicines “Ecosystem”
The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Impact of delisting OTC medicines from reimbursement list
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
Network medicines™
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
In development new medicines for women
Regulatory roadmap for nanotechnology based medicines
Translational medicines “Ecosystem”